MannKind reported $90.2M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Adma Biologics USD 114.5M 24.66M Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Insmed USD 305.96M 42.16M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
MacroGenics USD 20.8M 20.43M Mar/2026
MannKind USD 90.2M 21.76M Mar/2026
Merck USD 16.29B 110M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Novavax USD 147.14M 76.69M Dec/2025
Novo Nordisk DKK 12.53B 2.44B Dec/2025
Pfizer USD 14.5B 3.08B Mar/2026
Sanofi EUR 11.24B 60M Mar/2026
Xencor USD 4.51M 23.73M Mar/2026